Equities Analysts Set Expectations for Corcept Therapeutics Incorporated's Q2 2025 Earnings (NASDAQ:CORT)

Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Stock analysts at Zacks Research raised their Q2 2025 earnings per share (EPS) estimates for Corcept Therapeutics in a research note issued on Monday, April 8th. Zacks Research analyst K. Das now expects that the biotechnology company will earn $0.26 per share for the quarter, up from their prior forecast of $0.25. The consensus estimate for Corcept Therapeutics' current full-year earnings is $0.92 per share. Zacks Research also issued estimates for Corcept Therapeutics' Q3 2025 earnings at $0.25 EPS, Q4 2025 earnings at $0.38 EPS and FY2025 earnings at $1.10 EPS.

A number of other equities analysts have also commented on the company. StockNews.com raised Corcept Therapeutics from a "buy" rating to a "strong-buy" rating in a research note on Saturday, February 24th. Canaccord Genuity Group boosted their price objective on Corcept Therapeutics from $37.00 to $38.00 and gave the stock a "buy" rating in a research note on Wednesday, December 13th. HC Wainwright reduced their price objective on Corcept Therapeutics from $34.00 to $28.00 and set a "buy" rating on the stock in a research note on Tuesday, January 2nd. Finally, Truist Financial boosted their price objective on Corcept Therapeutics from $36.00 to $42.00 and gave the stock a "buy" rating in a research note on Friday, February 16th. Two equities research analysts have rated the stock with a hold rating, four have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Corcept Therapeutics currently has an average rating of "Moderate Buy" and an average price target of $33.79.

Corcept Therapeutics Stock Up 5.1 %

NASDAQ:CORT traded up $1.23 during trading hours on Tuesday, reaching $25.46. The company had a trading volume of 855,617 shares, compared to its average volume of 1,525,534. The stock has a 50-day moving average of $23.71 and a two-hundred day moving average of $25.82. Corcept Therapeutics has a one year low of $20.87 and a one year high of $34.28. The firm has a market capitalization of $2.64 billion, a PE ratio of 26.80 and a beta of 0.48.

Corcept Therapeutics (NASDAQ:CORT - Get Free Report) last announced its quarterly earnings results on Thursday, February 15th. The biotechnology company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.25 by $0.03. Corcept Therapeutics had a return on equity of 21.98% and a net margin of 21.86%. The firm had revenue of $135.41 million for the quarter, compared to analysts' expectations of $129.27 million. During the same period in the prior year, the business posted $0.14 earnings per share. The business's revenue was up 31.4% compared to the same quarter last year.

Insider Activity

In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company's stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $22.00, for a total value of $48,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. In related news, Director Daniel N. Swisher, Jr. sold 2,200 shares of the company's stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $22.00, for a total value of $48,400.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, CAO Joseph Douglas Lyon sold 1,000 shares of the company's stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $26.00, for a total value of $26,000.00. Following the completion of the sale, the chief accounting officer now owns 6,774 shares of the company's stock, valued at approximately $176,124. The disclosure for this sale can be found here. Insiders have sold 83,783 shares of company stock valued at $2,118,996 over the last 90 days. 18.60% of the stock is owned by company insiders.

Institutional Investors Weigh In On Corcept Therapeutics

Several large investors have recently modified their holdings of the business. GAMMA Investing LLC increased its holdings in shares of Corcept Therapeutics by 90.6% in the first quarter. GAMMA Investing LLC now owns 1,218 shares of the biotechnology company's stock worth $31,000 after acquiring an additional 579 shares in the last quarter. PNC Financial Services Group Inc. increased its holdings in shares of Corcept Therapeutics by 28.4% in the fourth quarter. PNC Financial Services Group Inc. now owns 11,008 shares of the biotechnology company's stock worth $358,000 after acquiring an additional 2,432 shares in the last quarter. Vanguard Group Inc. increased its holdings in shares of Corcept Therapeutics by 2.6% in the fourth quarter. Vanguard Group Inc. now owns 9,537,532 shares of the biotechnology company's stock worth $309,779,000 after acquiring an additional 239,887 shares in the last quarter. Wellington Management Group LLP bought a new position in shares of Corcept Therapeutics during the fourth quarter worth about $1,312,000. Finally, Goldman Sachs Group Inc. grew its holdings in shares of Corcept Therapeutics by 30.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 532,760 shares of the biotechnology company's stock worth $17,304,000 after buying an additional 124,185 shares in the last quarter. 93.61% of the stock is currently owned by institutional investors.

Corcept Therapeutics Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery.